期刊
CANCER RESEARCH
卷 80, 期 11, 页码 2217-2229出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-19-2908
关键词
-
类别
资金
- Bio & Medical Technology Development Program of the National Research Foundation - Korean government (MSIT) [2019M3E5D1A01069361]
- National Research Foundation of Korea [2019M3E5D1A01069361] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Stemness and epithelial-mesenchymal transition (EMT) are two fundamental characteristics of metastasis that are controlled by diverse regulatory factors, including transcription factors. Compared with other subtypes of breast cancer, basal-type or triple-negative breast cancer (TNBC) has high frequencies of tumor relapse. However, the role of alpha-globin transcription factor CP2 (TFCP2) has not been reported as an oncogenic driver in those breast cancers. Here, we show that TFCP2 is a potent factor essential for EMT, stemness, and metastasis in breast cancer. TFCP2 directly bound promoters of EGF and TGF alpha to regulate their expression and stimulate autocrine signaling via EGFR. These findings indicate that TFCP2 is a new antimetastatic target and reveal a novel regulatory mechanism in which a positive feedback loop comprising EGF/TGF alpha and AKT can control malignant breast cancer progression. Significance: TFCP2 is a new antimetastatic target that controls TNBC progression via a positive feedback loop between EGF/TGF alpha and the AKT signaling axis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据